Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg
Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg

Why this Hong Kong tycoon’s family backed biotech firm ditches the city for Nasdaq listing

  • Investment sentiment has soured for Hong Kong-traded pharma and biotech stocks on China’s drug price reforms
  • Hang Seng Index has lost 13.6 per cent in 2018 versus Nasdaq’s 3.9 per cent drop

Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg
Hong Kong aspires to overtake Nasdaq in the number of mainland Chinese biotech listings by 2023. Photo: Bloomberg
READ FULL ARTICLE